South Korea's Celltrion aims to set up China JV within first half of 2019: chairman
Reuters
Published Jan 05, 2019 11:06PM ET
South Korea's Celltrion aims to set up China JV within first half of 2019: chairman
SEOUL (Reuters) - South Korean drugmaker Celltrion Inc (KS:068270) aims to set up a joint venture in China within the first half of this year, and begin selling products in the country next year, its chairman said on Sunday.
"Since last year, we've been pushing on with a plan to set up a joint venture in China," Chairman Seo Jung Jin told reporters. The firm has been in talks with several Chinese companies, he said, declining to elaborate.
Celltrion sells drugs known as biosimilars, mainly to Europe and the United States.
It is South Korea's third-largest company by market value, after Samsung Electronics Co Ltd (KS:005930) and chipmaker SK Hynix Inc (KS:000660), according to the Korea Stock Exchange.
On Friday, it said it would build a third domestic plant and is continuing to review potential manufacturing sites overseas.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.